NBTX
NanobiotixNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.99B
P/E Ratio
—
EPS
$-0.58
Beta
0.58
52W High
$57.14
52W Low
$3.81
50-Day MA
$35.92
200-Day MA
$23.94
Dividend Yield
—
Profit Margin
-73.50%
Forward P/E
588.24
PEG Ratio
—
About Nanobiotix
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.
Fundamentals
| Revenue (TTM) | $32.59M |
| Gross Profit (TTM) | $32.59M |
| EBITDA | $-10.49M |
| Operating Margin | -196.40% |
| Return on Equity | -198.70% |
| Return on Assets | -10.10% |
| Revenue/Share (TTM) | $0.68 |
| Book Value | $-2.04 |
| Price-to-Book | 65.02 |
| Price-to-Sales (TTM) | 61.02 |
| EV/Revenue | 61.08 |
| EV/EBITDA | -2.45 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 186.80% |
| Shares Outstanding | $48.50M |
| Float | $31.07M |
| % Insiders | 0.00% |
| % Institutions | 11.78% |
Historical Volatility
HV 10-Day
136.31%
HV 20-Day
133.09%
HV 30-Day
113.37%
HV 60-Day
114.07%
HV Rank
72.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($41.32 target)
1
Strong Buy5
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026